Platelet aggregation signaling pathways

Platelet aggregation signaling pathways are the coordinated series of molecular events that lead to the activation and clumping of platelets to form a blood clot [1.1.1, 1.3.1]. These pathways are triggered by various agonists, including collagen, thrombin, adenosine diphosphate (ADP), and thromboxane A2, which bind to specific receptors such as glycoprotein VI (GPVI), protease-activated receptors (PAR1/4), and purinergic receptors (P2Y1/12) [1.1.2, 1.4.1]. The signaling cascades involve secondary messengers like calcium ions and diacylglycerol, which promote platelet shape change, granule secretion, and the activation of integrin alpha-IIb/beta-3 (GPIIb/IIIa) [1.1.3, 1.1.4]. Once activated, GPIIb/IIIa binds fibrinogen, facilitating platelet-to-platelet adhesion and thrombus stabilization [1.2.1, 1.3.2]. While these pathways are vital for preventing blood loss after injury (hemostasis), their pathological activation can cause arterial thrombosis, leading to myocardial infarction and stroke [1.3.3, 1.5.1]. Antiplatelet drugs target various nodes within these pathways—such as aspirin inhibiting cyclooxygenase-1 or clopidogrel blocking the P2Y12 receptor—to reduce the risk of thrombotic events in patients with cardiovascular disease [1.4.2, 1.4.4].

Other names

Platelet activation pathwaysPlatelet signalingHemostatic signaling cascades

Inhibition of platelet activation and aggregation by targeting specific receptors (e.g., P2Y12, PAR1, GPIIb/IIIa) or enzymes (e.g., COX-1) involved in signaling cascades to prevent thrombus formation [1.3.2, 1.4.1, 1.4.4].